BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 9205848)

  • 1. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
    Burrell LM; Johnston CI
    Drugs Aging; 1997 Jun; 10(6):421-34. PubMed ID: 9205848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
    Pitt B; Chang P; Timmermans PB
    Cardiovasc Drugs Ther; 1995 Oct; 9(5):693-700. PubMed ID: 8573552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A; Giner V
    Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Ramahi TM
    Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor blockers. A new class of antihypertensive drugs.
    Velasquez MT
    Arch Fam Med; 1996 Jun; 5(6):351-6. PubMed ID: 8640326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valsartan: more than a decade of experience.
    Black HR; Bailey J; Zappe D; Samuel R
    Drugs; 2009; 69(17):2393-414. PubMed ID: 19911855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-II receptor antagonists: their place in therapy.
    Kirk JK
    Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
    Burrell LM
    Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.
    Eberhardt RT; Kevak RM; Kang PM; Frishman WH
    J Clin Pharmacol; 1993 Nov; 33(11):1023-38. PubMed ID: 8300885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
    Martin J; Krum H
    Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
    Goa KL; Wagstaff AJ
    Drugs; 1996 May; 51(5):820-45. PubMed ID: 8861549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dosage equivalents of AT1-receptor antagonists available in Germany].
    Dominiak P; Häuser W
    Dtsch Med Wochenschr; 2003 Oct; 128(44):2315-8. PubMed ID: 14593575
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
    Byyny RL; Merrill DD; Bradstreet TE; Sweet CS
    Cardiovasc Drugs Ther; 1996 Jul; 10(3):313-9. PubMed ID: 8877074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
    Krasnikova TL
    Klin Med (Mosk); 1996; 74(3):17-21. PubMed ID: 8926692
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
    Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fast-acting sartan. High blood pressure therapy without long waiting time].
    MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866306
    [No Abstract]   [Full Text] [Related]  

  • 20. The future role of losartan.
    Hansson L
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.